Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Brain Neoplasms 5Neoplasms 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Postoperative Complications 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Ovarian Cysts 1Myofibroma 1Lung Neoplasms 1Liver Neoplasms 1Hematologic Diseases 1Endobronchial Metastases 1Encephalocele 1Ear Neoplasms 1Cholecystitis 1Breast Neoplasms 1Brain Injuries 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × Remifentanil × Clear all
NCT06003218 2025-04-02

Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation

Peking University First Hospital

Phase NA Completed
88 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡